Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
© NHSBT

Radcliffe Department of Medicine's Professor David Roberts, who is also Associate Medical Director, NHS Blood and Transplant, is co-leading an NHS Blood and Transplant programme to collect convalescent plasma from people who have recovered from COVID-19 to support a national clinical trial. The UK Department of Health and Social Care announced the programme on Saturday 25 April.

Professor Hugh Watkins, who heads the Radcliffe Department of Medicine said “We are keen to bring the expertise and facilities we have here at the department to help solve what is likely to be the greatest public health crisis of our generation.”

“Transfusion of antibody-containing plasma from recovered patients has been an effective treatment strategy for other viral diseases, so this is an important trial.”

The transfusions will be done through the existing REMAP-CAP trial and further trial options are being explored.

Read more on the Radcliffe Department of Medicine website

Read more about the trial on the NHS Blood and Transplant website

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.